Actinium Pharmaceuticals, Inc.
ATNM
$1.52
-$0.03-1.94%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 8.94M | 2.69M | 2.83M | 3.59M | 2.96M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.64M | 7.51M | 12.60M | 12.42M | 9.60M |
| Operating Income | -16.64M | -7.51M | -12.60M | -12.42M | -9.60M |
| Income Before Tax | -15.94M | -6.65M | -11.57M | -11.35M | -8.67M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.94M | -6.65M | -11.57M | -11.35M | -8.67M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.94M | -6.65M | -11.57M | -11.35M | -8.67M |
| EBIT | -16.64M | -7.51M | -12.60M | -12.42M | -9.60M |
| EBITDA | -16.43M | -7.45M | -12.40M | -12.23M | -9.38M |
| EPS Basic | -0.51 | -0.21 | -0.37 | -0.38 | -0.31 |
| Normalized Basic EPS | -0.32 | -0.13 | -0.23 | -0.24 | -0.19 |
| EPS Diluted | -0.51 | -0.21 | -0.37 | -0.38 | -0.31 |
| Normalized Diluted EPS | -0.32 | -0.13 | -0.23 | -0.24 | -0.19 |
| Average Basic Shares Outstanding | 31.20M | 31.20M | 31.07M | 30.10M | 27.89M |
| Average Diluted Shares Outstanding | 31.20M | 31.20M | 31.07M | 30.10M | 27.89M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |